Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 9.53B |
| Revenue (ttm) | 1.05B |
| Net Income (ttm) | 402.00M |
| Shares Out | 94.20M |
| EPS (ttm) | 4.09 |
| PE Ratio | 24.56 |
| Forward PE | 38.76 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $100.48 |
| Previous Close | $100.26 |
| Change ($) | 0.22 |
| Change (%) | 0.22% |
| Day's Open | 100.52 |
| Day's Range | 99.61 - 101.53 |
| Day's Volume | 604,169 |
| 52-Week Range | 86.02 - 136.26 |
SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June ...
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021.
Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021 fi...
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021.
SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people living ...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Of...
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesday...
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy o...
Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021.
The stock is being added to a mid-cap index.
NEW YORK, March 24, 2021 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in ...
SAN DIEGO, March 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an...
Just like that, we are less than two weeks from the end of the first quarter. While it has been a very positive one for investors, the rise in interest rates has brought in much higher volatility and ha...
Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years, although their stock prices have lagged, due to Covid-19 related disrupti...
A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at $90 levels. B...
SAN DIEGO, March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021.
Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment...
SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase...
Our theme of Out Of Favor Health Care Stocks includes companies that have robust revenue growth and improving margins, and yet have not rallied much over the last year or so, due to Covid-19 related dis...
Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91, which be...
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provided full-y...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes...
Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on ...
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales r...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021. K...
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is up just 1...
Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is t...
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year to $0.97,...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 20...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorma...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in r...
Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes heal...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
Investors seeking strong growth companies to invest in should watch Credit Acceptance Corporation, RenaissanceRe and Neurocrine Biosciences. The post 3 Companies to Invest In for Mammoth Growth in 2021 ...
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...
With earnings season about to kick off, investors are being forced into a different sort of earnings season.
SAN DIEGO and BOSTON, Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for people with...
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November...
SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS® (opicapone) capsules, ...
Ongentys, an add-on treatment for patients with Parkinson's disease, is entering the market soon.
Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma
About NBIX
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the... [Read more...]
| Industry Biotechnology | IPO Date May 23, 1996 |
| CEO Kevin Gorman | Employees 865 |
| Stock Exchange NASDAQ | Ticker Symbol NBIX |
Financial Performance
In 2020, NBIX's revenue was $1.05 billion, an increase of 32.71% compared to the previous year's $788.10 million. Earnings were $407.30 million, an increase of 1,000.81%.
Analyst Forecasts
According to 25 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is 122.35, which is an increase of 21.77% from the latest price.